Teva Pharmaceutical Industries (TEVA) Operating Leases (2018 - 2026)

Teva Pharmaceutical Industries has disclosed Operating Leases across 9 years of filings, most recently posting $280.0 million for Q1 2026.

• Quarterly Operating Leases fell 2.78% year-over-year to $280.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $280.0 million (down 2.78% YoY) and the FY2025 annual result came in at $288.0 million, down 2.7% from the prior year.
• Operating Leases retreated to $280.0 million in Q1 2026, from $288.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $442.0 million in Q4 2022 and troughed at $280.0 million in Q1 2026.
• A 5-year average of $322.8 million and a median of $296.0 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases increased 6.25% — and 2023, when it slipped 27.6%.
• Tracing TEVA's Operating Leases over 5 years: stood at $442.0 million in 2022, then decreased by 27.6% to $320.0 million in 2023, then retreated by 7.5% to $296.0 million in 2024, then slipped by 2.7% to $288.0 million in 2025, then fell by 2.78% to $280.0 million in 2026.
• Business Quant data shows TEVA's Operating Leases at $280.0 million in Q1 2026, $288.0 million in Q4 2025, and $283.0 million in Q3 2025.